9AT Manager News
← All updates

Sands Capital Alternatives, LLC

Sands Capital Alternatives files Q2 2026 13F with 24 reported rows

August 13, 2026 filing Manager profile

Summary: Sands Capital Alternatives, LLC filed a public Form 13F-HR on August 13, 2026 for the quarter ended June 30, 2026. The SEC information table lists 24 reported rows, with the largest reported value-field entries for Alamar Biosciences, Nu Holdings, Klaviyo, Beta Bionics, and Spyglass Pharma.

Why it matters: The filing gives due-diligence readers a narrow public snapshot of Sands Capital Alternatives' reported listed-security holdings for the quarter, while remaining incomplete as a view of the broader Sands Capital platform, private-market activity, performance, or investment outlook.

9AT filing context: Public SEC 13F context for period 2026-06-30 shows 24 information-table rows and reported value fields summing to 613,546,175 as presented in the XML; ADV identity context maps Sands Capital Alternatives, LLC to CIK 0001846444 / CRD 155517 / SEC file 801-72115 and about $5.4B in reported regulatory AUM/profile scale.

Summary

Sands Capital Alternatives, LLC filed a public Form 13F-HR on August 13, 2026 for the quarter ended June 30, 2026. The SEC submissions record identifies the filing as accession 0001846444-26-000009, and the primary Form 13F document names Sands Capital Alternatives, LLC with CRD 000155517 and SEC adviser file 801-72115.

The associated SEC information table lists 24 reported rows. The largest reported value-field entries are Alamar Biosciences, Nu Holdings, Klaviyo, Beta Bionics, and Spyglass Pharma. This draft treats those entries as reported SEC 13F fields for Sands Capital Alternatives specifically, not as a complete view of the broader Sands Capital platform, private-market activity, performance, or investment merit.

Why it matters

For due-diligence readers, a new 13F can provide a delayed public snapshot of listed long securities and certain reportable instruments. For an alternatives-labeled adviser, the source is useful mainly as a bounded reporting signal: it shows a public listed-security snapshot for this filing entity, while leaving the rest of the platform and any private-market activity outside the filing’s scope.

The signal should not be overread. Form 13F does not show cash, short positions, non-reportable instruments, private holdings, investor demand, manager quality, or performance. The reported value fields should be used only as filing-derived context and should not be treated as total AUM or a recommendation.

Source notes

9AT filing context

Public SEC 13F context for the quarter ended June 30, 2026 shows 24 information-table rows. The parsed information table shows reported value fields summing to 613,546,175 as presented in the XML, with the largest rows by reported value field for Alamar Biosciences, Nu Holdings, Klaviyo, Beta Bionics, and Spyglass Pharma.

Public adviser/profile context reviewed by 9AT maps Sands Capital Alternatives, LLC to CIK 0001846444, CRD 155517, SEC file 801-72115, and about $5.4 billion in reported regulatory AUM/profile scale. That adviser context is identity and scale background only; it does not validate the 13F holdings, imply investor demand, describe the full Sands Capital platform, or support any investment recommendation.

What to watch

Watch future 13F filings for amendments, changes in the largest reported entries, row-count changes, or shifts in issuer concentration. Also watch public adviser filings and primary Sands Capital announcements for entity-scope changes, since 13F records alone do not describe the broader platform or private-market activity.

Source links